![]() ![]() The expert panel of the 2018 ACC/AHA/MS Guidelines (Grundy et al., 2019) defines recommended intensity of statin therapy on the basis of the average expected LDL-C response to specific statin and dose. Intensity of statin therapy in primary and secondary prevention: It may not be appropriate to prescribe statin therapy for some patients (see exceptions and exclusions for the complete list). Adherence to statin therapy is not calculated in this measure. There is only one performance rate calculated for this measure: the weighted average of the three populations. ![]() Patients with an allowable denominator exception should be removed from the denominator of the measure and reported as a valid exception. Patients who meet the denominator criteria for inclusion, but are not prescribed or using statin therapy, will NOT meet performance for this measure unless they have an allowable denominator exception. Statin medication "samples" provided to patients can be documented as "current statin therapy" if documented in the medication list in health/medical record. Prescription or order does NOT need to be linked to an encounter or visit it may be called to the pharmacy. ONLY statin therapy meets the measure Numerator criteria (NOT other cholesterol lowering medications). Current statin therapy use must be documented in the patient's current medication list or ordered during the measurement period. ![]() If a patient has ANY previous laboratory result of LDL-C >= 190 mg/dL, report the highest value >= 190 mg/dL. The measure can be reported for all patients with a documented LDL-C level recorded as follows: In order for the patient to be included in the Initial Population, the patient must have ONE initial population-eligible visit, defined as follows: outpatient visit, initial or established office visit, face-to-face interaction, preventive care services, or annual wellness visit Initial Population Guidance for Encounter: If NO, patient does NOT meet Initial Population criteria and is NOT eligible for measure inclusion If YES, meets Initial Population 3 risk category Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period If YES, meets Initial Population 2 risk category Patients aged >= 20 years at the beginning of the measurement period who have ever had a laboratory test result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia If YES, meets Initial Population 1 risk category Use the following process to prevent counting patients more than once.Īll patients who were previously diagnosed with or currently have an active diagnosis of clinical ASCVD, including an ASCVD procedure, before the end of the measurement period The initial population covers three distinct populations. Patients with end-stage renal disease (ESRD)Ĭenters for Medicare & Medicaid Services (CMS) Patients with active liver disease or hepatic disease or insufficiency Patients who are receiving palliative or hospice care Patients with statin-associated muscle symptoms or an allergy to statin medication Patients who have a diagnosis of rhabdomyolysis at any time during the measurement period Patients who are breastfeeding at any time during the measurement period Patients who have a diagnosis of pregnancy at any time during the measurement period ![]() Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period Patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes Patients aged >= 20 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >=190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia *Patients aged 40-75 years with a diagnosis of diabetesĪll patients who were previously diagnosed with or currently have an active diagnosis of clinical ASCVD, including an ASCVD procedure *Patients aged >= 20 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia OR *All patients who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure OR Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |